{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:41:15Z","timestamp":1792078875310,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02269-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:03:55Z","timestamp":1764738235000},"page":"377-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Elamipretide: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2269_CR1","unstructured":"US FDA. FDA grants accelerated approval to first treatment for Barth syndrome [media release]. 19 Sep 2025. https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/3f38219."},{"key":"2269_CR2","unstructured":"US FDA. FORZINITY (elamipretide) injection, for subcutaneous use. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215244s000lbl.pdf. Accessed 10 Nov 2025."},{"issue":"4","key":"2269_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2217\/fca-2023-0008","volume":"19","author":"HN Sabbah","year":"2023","unstructured":"Sabbah HN, Taylor C, Vernon HJ. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. Future Cardiol. 2023;19(4):211\u201325.","journal-title":"Future Cardiol"},{"issue":"2","key":"2269_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10741-020-10031-3","volume":"26","author":"HN Sabbah","year":"2021","unstructured":"Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Heart Fail Rev. 2021;26(2):237\u201353.","journal-title":"Heart Fail Rev"},{"key":"2269_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jpeds.2019.09.074","volume":"217","author":"PC Miller","year":"2020","unstructured":"Miller PC, Ren M, Schlame M, et al. A Bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population. J Pediatr. 2020;217:139\u201344.","journal-title":"J Pediatr"},{"key":"2269_CR6","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics granted Fast Track designation for elamipretide for the treatment of Leber\u2019s hereditary optic neuropathy [media release]. 18 Dec 2017. https:\/\/stealthbt.com\/."},{"key":"2269_CR7","unstructured":"Stealth BioTherapeutics. FDA grants Rare Pediatric Disease designation to Stealth BioTherapeutics for elamipretide for the treatment of Barth syndrome [media release]. 03 Mar 2020. https:\/\/stealthbt.com\/."},{"key":"2269_CR8","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics granted Orphan Drug designation of elamipretide for treatment of Leber\u2019s hereditary optic neuropathy [media release]. 30 Apr 2018. https:\/\/stealthbt.com\/."},{"key":"2269_CR9","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics receives Orphan Drug designation from the European Medicines Agency for elamipretide for the treatment of Barth syndrome [media release]. 01 Jun 2021. https:\/\/stealthbt.com\/."},{"key":"2269_CR10","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics granted Fast Track designation for elamipretide for the treatment of dry age-related macular degeneration with geographic atrophy [media release]. 10 Dec 2018. https:\/\/stealthbt.com\/."},{"key":"2269_CR11","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics receives FDA Fast Track designation for rare disease indication [media release]. 07 Jan 2016. https:\/\/stealthbt.com\/."},{"key":"2269_CR12","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics granted Orphan Drug designation of elamipretide for treatment of patients with primary mitochondrial myopathy [media release]. 02 Oct 2017. https:\/\/stealthbt.com\/."},{"key":"2269_CR13","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics receives Orphan Drug designation from the European Medicines Agency for elamipretide for the treatment of myopathic mitochondrial DNA depletion syndrome [media release]. 31 May 2022. https:\/\/stealthbt.com\/."},{"key":"2269_CR14","unstructured":"United States Securities and Exchange Commission. 2021. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1696396\/000156459021017843\/mito-20f_20201231.htm. Accessed 10 Nov 2025."},{"key":"2269_CR15","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics enters into exclusive licensing agreement with Pharmanovia to commercialize elamipretide for the treatment of Barth syndrome in Europe and key global territories [media release]. 30 May 2023. https:\/\/stealthbt.com\/."},{"key":"2269_CR16","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics strengthens IP portfolio with issuance of U.S. patents covering elamipretide for Barth syndrome [media release]. 23 Aug 2021. https:\/\/stealthbt.com\/."},{"issue":"8","key":"2269_CR17","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","volume":"171","author":"HH Szeto","year":"2014","unstructured":"Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029\u201350.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"2269_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gim.2024.101138","volume":"26","author":"WR Thompson","year":"2024","unstructured":"Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):1\u201310.","journal-title":"Genet Med"},{"issue":"3","key":"2269_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","volume":"23","author":"WR Thompson","year":"2021","unstructured":"Thompson WR, Hornby B, Manuel R, et al. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471\u20138.","journal-title":"Genet Med"},{"issue":"1","key":"2269_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02469-5","volume":"17","author":"B Hornby","year":"2022","unstructured":"Hornby B, Thompson WR, Almuqbil M, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022;17(1):1\u20139.","journal-title":"Orphanet J Rare Dis"},{"key":"2269_CR21","doi-asserted-by":"crossref","unstructured":"Prasanpanich M, Husain M, Halnon NJ, et al. Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene. Cardiovasc Pathol. 2025;79(107749):1\u20135.","DOI":"10.1016\/j.carpath.2025.107749"},{"issue":"2","key":"2269_CR22","first-page":"1","volume":"9","author":"L Ortmann","year":"2025","unstructured":"Ortmann L, Velasco D, Cole J. Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. Eur Heart J Case Rep. 2025;9(2):1\u20136.","journal-title":"Eur Heart J Case Rep"},{"issue":"4 Suppl","key":"2269_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2025.02.707","volume":"44","author":"M Marshall","year":"2025","unstructured":"Marshall M, Chase C, Lamour JM, et al. Significantly improved cardiac function in neonate with Barth syndrome on investigational drug elamipretide. J Heart Lung Transplant. 2025;44(4 Suppl):S331.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"2269_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100628","volume":"5","author":"JP Ehlers","year":"2025","unstructured":"Ehlers JP, Hu A, Boyer D, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100628.","journal-title":"Ophthalmol Sci"},{"issue":"3","key":"2269_CR25","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","volume":"101","author":"A Karaa","year":"2023","unstructured":"Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238\u201352.","journal-title":"Neurology"},{"issue":"14","key":"2269_CR26","doi-asserted-by":"publisher","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","volume":"90","author":"A Karaa","year":"2018","unstructured":"Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212\u201321.","journal-title":"Neurology"},{"issue":"4","key":"2269_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcsm.12559","volume":"11","author":"A Karaa","year":"2020","unstructured":"Karaa A, Haas R, Goldstein A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909\u201318.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2269_CR28","unstructured":"Stealth BioTherapeutics. Stealth BioTherapeutics announces achievement of 50% enrollment target in Phase 3 ReNEW study of elamipretide in patients with dry age-related macular degeneration [media release]. 13 Mar 2025. https:\/\/stealthbt.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02269-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02269-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02269-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:35:57Z","timestamp":1772764557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02269-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2269"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02269-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}